Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Historic Interest Coverage Ratio for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to 928119.2.

  • Inhibikase Therapeutics' Interest Coverage Ratio fell 41696255.1% to 928119.2 in Q1 2022 from the same period last year, while for Dec 2022 it was 3625721.6, marking a year-over-year decrease of 48909522.26%. This contributed to the annual value of 741.16 for FY2021, which is 67316.52% down from last year.
  • As of Q1 2022, Inhibikase Therapeutics' Interest Coverage Ratio stood at 928119.2, which was down 41696255.1% from 31907.98 recorded in Q4 2021.
  • In the past 5 years, Inhibikase Therapeutics' Interest Coverage Ratio ranged from a high of 52.08 in Q2 2020 and a low of 928119.2 during Q1 2022
  • In the last 3 years, Inhibikase Therapeutics' Interest Coverage Ratio had a median value of 222.54 in 2021 and averaged 109939.28.
  • In the last 5 years, Inhibikase Therapeutics' Interest Coverage Ratio tumbled by 20598.01% in 2021 and then crashed by 41696255.1% in 2022.
  • Quarter analysis of 3 years shows Inhibikase Therapeutics' Interest Coverage Ratio stood at 168.21 in 2020, then tumbled by 18869.2% to 31907.98 in 2021, then plummeted by 2808.74% to 928119.2 in 2022.
  • Its Interest Coverage Ratio was 928119.2 in Q1 2022, compared to 31907.98 in Q4 2021 and 28477.96 in Q3 2021.